Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c9faf0ff03b05a5395781acdee289410 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f75cc61295b6c8882ca116d5fb634dca http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2cb03ff309c31e766cf428b88c1dd9a6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7e29d5f3dd73938f1ad5248ca11fbb6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0e45cde95d5a9f979ffdbc9e940715bc |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-715 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N43-04 |
filingDate |
2008-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2012-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_56706c4467ffa81a1b7a6f62546fc03a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f42b8a8c5a6fbf34072f28779527374 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ecd2d5243d214c0d3b0b2e7d5493891e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_925cf782c5306e1ec3f7ce8e78bdcc1f |
publicationDate |
2012-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-8119616-B2 |
titleOfInvention |
Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety |
abstract |
The present invention relates to a composition comprising an inclusion complex of a cyclodextrin and quinazoline containing zinc-binding moiety based derivatives. The cyclodextrin is preferable a β-cyclodextrin or a derivative thereof. The quinazolines have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8846912-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9108929-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9024024-B2 |
priorityDate |
2007-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |